P-34 Does the chemotherapeutic efficacy of trifluridine/tipiracil plus bevacizumab change depend on pre-treatment vascular endothelial growth factor inhibitors?

H Osumi,O Akira,K Shimozaki,I Nakayama,T Wakatsuki,D Takahari,K Chin,K Yamaguchi,E Shinozaki

doi:10.1016/j.annonc.2022.04.125

P-34 Does the chemotherapeutic efficacy of trifluridine/tipiracil plus bevacizumab change depend on pre-treatment vascular endothelial growth factor inhibitors?

H Osumi, O Akira + Show 7 more

Open Access

PDF Available

https://doi.org/10.1016/j.annonc.2022.04.125

Copy DOI

Export

Save

Cite

Journal: Annals of Oncology

Publication Date: Jun 1, 2022

Affiliation: Japanese Foundation For Cancer Research

#Vascular Endothelial Growth Factor Inhibitors #Pre-treatment Vascular Endothelial Growth Factor #Bevacizumab #Vascular Endothelial Growth Factor #Growth Factor Inhibitors #mCRC Patients #Ramucirumab #Aflibercept #Colorectal Cancer #Metastatic Colorectal Cancer Patients

Abstract
Full-Text PDF
Similar Papers

Abstract

Listen

Trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) is widely used as one of salvage line treatment options in metastatic colorectal cancer (mCRC) patients. In Japan, three vascular endothelial growth factor (VEGF) inhibitors, BEV, ramucirumab (RAM), and aflibercept (AFL), are approved for mCRC patients with second-line chemotherapy including irinotecan. It remains unclear the effect of the difference of pretreatment VEGF inhibitors in clinical outcomes of FTD/TPI plus BEV.

Full Text

Published Version (Free)

View/Download pdf

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

P-34 Does the chemotherapeutic efficacy of trifluridine/tipiracil plus bevacizumab change depend on pre-treatment vascular endothelial growth factor inhibitors?